MT-2

MT-2, short for Melanotan-2, is a synthetic cyclic peptide analog of alpha-melanocyte-stimulating hormone (alpha-MSH), developed by melanocortin researchers at the University of Arizona as part of a program to create potent, long-acting versions of the natural hormone ^[1]. Where its sibling Melanotan-1 was designed to be selective for the pigment receptor, MT-2 is a broadly nonselective melanocortin agonist, and that difference defines its character ^[1][5].

By activating the melanocortin-1 receptor, MT-2 stimulates the skin's pigment cells to make eumelanin, producing a tan that develops with little or no ultraviolet exposure ^[5]. Because it also activates the melanocortin-3 and melanocortin-4 receptors in the brain, it simultaneously drives central effects on sexual arousal and appetite, which is why users report both increased libido and reduced hunger ^[1][2].

The sexual-function side of this pharmacology proved so notable that a related melanocortin analog, bremelanotide (PT-141), was developed specifically as a treatment for sexual dysfunction; it acts mainly at the melanocortin-4 receptor and, after phase III trials, was approved by the US Food and Drug Administration in 2019 as Vyleesi for hypoactive sexual desire disorder in premenopausal women ^[2][3].

MT-2 itself, however, has never been approved as a medicine. It is sold and used illicitly, most often as a self-administered injection for cosmetic tanning, and dermatologists have repeatedly warned about it as an unlicensed, untested product; documented concerns include nausea, darkening and change of moles, and the appearance of new pigmented lesions ^[4][6].

Common effects include nausea, facial flushing, spontaneous erections, and darkening of existing moles and freckles. More serious concerns include reports of rhabdomyolysis and kidney injury, and case reports of melanoma or changing pigmented lesions with heavy use. It is an unapproved research compound with variable purity; any new or changing mole warrants prompt dermatologic review.

Melanotan II was designed in the late 1980s at the University of Arizona by a team including pharmacologist Mac Hadley and chemist Victor Hruby, who sought a superpotent cyclic analogue of alpha-melanocyte-stimulating hormone to promote protective skin pigmentation and reduce skin-cancer risk. During research it was found that the peptide also produced spontaneous erections in male subjects, a result formally reported by Hugh Wessells and colleagues in double-blind studies in 1998 and 2000. This unexpected pro-sexual activity was subsequently developed into a distinct, ring-opened drug, bremelanotide, which received FDA approval in 2019 for low sexual desire in women. Melanotan II itself was never approved and circulates as an unregulated research compound.

MT-2 is sought after for two striking effects packed into one peptide; it can produce durable, sun-independent tanning through melanocortin-1 receptor activation and pronounced pro-sexual and appetite-suppressing effects through central melanocortin-4 receptor activation. Its potency is what makes it pharmacologically distinctive among tanning agents, and its lineage is notable, having directly seeded an FDA-approved medicine. In the interest of honesty, MT-2 is an unapproved compound with a real side-effect profile, including nausea, facial flushing, and darkening of existing moles, and it should be treated as an experimental research peptide rather than a sanctioned therapy.